acadia pharmaceuticals inc shares rose 16 to 3140 in postmarket trade monday after the company said it plans to resubmit its supplemental new drug application for pimavanserin to treat hallucinations and delusions associated with alzheimers disease psychosis acadia plans to resubmit the application in the first quarter of 2022 after the food and drug administration rejected it in april the company is trying to expand the label for pimavanserin which is already approved to treat hallucinations and delusions associated with parkinsons disease psychosis and is marketed as nuplazid following our recent meetings with the fda we plan to resubmit our snda for pimavanserin narrowing the proposed indication from dementiarelated psychosis to alzheimers disease psychosis said chief executive steve davis